Ubs Group Ag Alnylam Pharmaceuticals, Inc. Call Options Transaction History

Ubs Group Ag

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 13, 2024	BUY	$146.51 - $198.2 $322,322 - $436,040	2,200 Added 28.21%	10,000 $1.49 Million
Q4 2023 Feb 09, 2024	BUY	$151.41 - $196.57 $1.18 Million - $1.53 Million	7,800 New	7,800 $1.49 Million
Q4 2022 Feb 08, 2023	BUY	$185.53 - $241.31 $371,060 - $482,620	2,000 New	2,000 $475,000
Q4 2018 Feb 14, 2019	SELL	$62.67 - $88.33 $2.27 Million - $3.21 Million	-36,300 Reduced 51.13%	34,700 $2.53 Million
Q3 2017 Nov 14, 2017	SELL	$72.53 - $118.27 $3.99 Million - $6.5 Million	-55,000 Reduced 43.65%	71,000 $8.34 Million
Q2 2017 Aug 14, 2017	BUY	N/A	126,000	126,000 $10.1 Million

643

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $28.7B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.